By George Mwangi

Special to Dow Jones Newswires

The European Commission has granted marketing authorization to pharmaceutical company Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford, the British university said Thursday.

The two-dose Ebola vaccine regimen, developed by Johnson & Johnson's Janssen, is specifically designed to induce long-term immunity against the Ebola virus in adults and children aged one year and above, the university said.

The Ebola vaccine has already been deployed in the North Kivu region of the Democratic Republic of the Congo and Rwanda, it added.

Write to Barcelona Editors at barcelonaeditors@dowjones.com

(END) Dow Jones Newswires

July 02, 2020 08:22 ET (12:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson